- $433.99m
- $102.80m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.29 | ||
| Price to Tang. Book | 1.29 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -71.88% | ||
| Return on Equity | -73.44% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 19.75 | 40.66 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
Directors
- Dieter Weinand NEC (61)
- Robert Coffin PRE (56)
- Philip Astley-Sparke CEO (49)
- Jean Franchi CFO (54)
- Colin Love COO (63)
- Pamela Esposito OTH (47)
- Tanya Lewis OTH (50)
- Sushil Patel OTH (50)
- Kapil Dhingra IND (61)
- Hyam Levitsky IND (63)
- Christy Oliger IND (51)
- Paolo Pucci IND (60)
- Jason Rhodes IND (52)
- Joseph Slattery IND (56)
- Sander Slootweg IND (52)
- Last Annual
- March 31st, 2025
- Last Interim
- June 30th, 2025
- Incorporated
- July 5th, 2017
- Public Since
- July 20th, 2018
- No. of Shareholders
- 7
- No. of Employees
- 479
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 78,055,846
- Address
- 500 Unicorn Park Dr, WOBURN, 01801-3377
- Web
- https://www.replimune.com/
- Phone
- +1 7812229600
- Contact
- Christopher Brinzey
- Auditors
- PricewaterhouseCoopers LLC
Upcoming Events for REPL
Q2 2026 Replimune Group Inc Earnings Release
Similar to REPL
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Replimune share price?
As of Today at 22:54 UTC, shares in Replimune are trading at $5.56. This share price information is delayed by 15 minutes.
How has the Replimune share price performed this year?
Shares in Replimune last closed at $5.56 and the price had moved by -46.02% over the past 365 days. In terms of relative price strength the Replimune share price has underperformed the S&P500 Index by -53.51% over the past year.
What are the analyst and broker recommendations for Replimune?
The overall consensus recommendation for Replimune is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Replimune dividend yield?
Replimune does not currently pay a dividend.
Does Replimune pay a dividend?
Replimune does not currently pay a dividend.
When does Replimune next pay dividends?
Replimune does not currently pay a dividend.
How do I buy Replimune shares?
To buy shares in Replimune you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Replimune?
As of the previous close price of $5.56, shares in Replimune had a market capitalisation of $433.99m.
Where are Replimune shares listed?
Here are the trading details for Replimune:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: REPL
What kind of share is Replimune?
Based on an overall assessment of its quality, value and momentum Replimune is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Replimune share price forecast for 2025?
The analyst consensus target price for shares in Replimune is $7.14. That is 28.42% above the last closing price of $5.56.
Analysts covering Replimune currently have a consensus Earnings Per Share (EPS) forecast of -$3.27 for the next financial year.
Find out moreWhat is the trend in the Replimune share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Replimune. Over the past six months, its share price has underperformed the S&P500 Index by -62.53%.
As of the last closing price of $5.56, shares in Replimune were trading -46.8% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Replimune PE Ratio?
The Replimune PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.56.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Replimune?
Replimune's management team is headed by:
- Dieter Weinand - NEC
- Robert Coffin - PRE
- Philip Astley-Sparke - CEO
- Jean Franchi - CFO
- Colin Love - COO
- Pamela Esposito - OTH
- Tanya Lewis - OTH
- Sushil Patel - OTH
- Kapil Dhingra - IND
- Hyam Levitsky - IND
- Christy Oliger - IND
- Paolo Pucci - IND
- Jason Rhodes - IND
- Joseph Slattery - IND
- Sander Slootweg - IND